Dr. Armin Graber joined Turning Point Therapeutics in June 2018 after holding various executive positions in both academia and the biotechnology industry in Europe and the U.S. He brings 30 years of experience in translational research, correlative sciences and diagnostic development, mainly in oncology. Most recently, Dr. Graber was vice president and head of research & product development and medical affairs at Genoptix. Previously, he held various global roles in companion diagnostics, correlative sciences and translational medicine at Novartis, served as vice president for translational research at BG Medicine, and was CEO and head of research & product development of Biocrates Life Sciences. He also served as chair of the department of Biomedical Sciences and Engineering and CEO of the University for Health Sciences, Medical Informatics and Technology (UMIT). Originally from Austria, Dr. Graber received a Ph.D. in Medical Informatics and Biostatistics from the University of Innsbruck, a Master of Science degree in technical mathematics and computer science from the Technical University of Graz, and a Priv.-Doz. in bioinformatics and translational research from the UMIT.